Literature DB >> 28509215

De novo acute hepatitis B in myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-related microscopic polyangiitis treated with corticosteroids.

Yoichi Iwafuchi1, Yuko Oyama2, Takashi Morita3, Akira Kamimura2, Shigeru Miyazaki4, Ichiei Narita5.   

Abstract

An 82-year-old female was referred to our hospital because of low-grade fever, anemia, and rapidly progressive nephritic syndrome. Her laboratory data showed mild proteinuria, mild renal failure, and the presence of myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody. A skin biopsy specimen taken from the erythematous purpura revealed neutrophilic infiltration around the blood vessels with fibrinoid changes in the vessel walls. A renal biopsy specimen revealed segmental necrotizing glomerulonephritis with fibro-cellular crescent formation without deposits of immunoglobulin or complement components, indicating microscopic polyangiitis. The use of corticosteroid treatment, including intravenous methylprednisolone, improved renal failure. After 4 years with low-dose maintenance corticosteroid therapy, she developed de novo acute hepatitis B, and entecavir was remarkably effective, showing a rapid recovery from liver dysfunction with jaundice. To prevent hepatitis B virus (HBV) reactivation and de novo acute hepatitis B induced by immunosuppressive or cytotoxic therapy, including corticosteroids alone, the measurement of HBV-related serological markers needs to be performed prior to the initiation of such therapy, even in renal diseases.

Entities:  

Keywords:  Corticosteroids; De novo acute hepatitis B; Entecavir; Hepatitis B virus reactivation; Immunosuppressive or cytotoxic therapy; Microscopic polyangiitis

Year:  2012        PMID: 28509215      PMCID: PMC5413723          DOI: 10.1007/s13730-012-0033-2

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  16 in total

1.  [Guidelines for the management of rapidly progressive glomerulonephritis].

Authors:  Hideto Sakai; Kiyoshi Kurokawa; Akio Koyama; Yoshihiro Arimura; Hiroshi Kida; Hidekazu Shigematsu; Satoshi Suzuki; Hiroshi Nihei; Hirofumi Makino; Naohiko Ueda; Tetsuya Kawamura; Fumitake Gejyo; Takao Saito; Takashi Harada; Yoshijuki Hiki; Masahara Yoshida
Journal:  Nihon Jinzo Gakkai Shi       Date:  2002-03

2.  Chronic hepatitis B: update 2009.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

3.  Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis.

Authors:  Nicholas Mansfield; Sally Hamour; Anne-Marie Habib; Ruth Tarzi; Jeremy Levy; Megan Griffith; Tom Cairns; H Terence Cook; Charles D Pusey; Alan D Salama
Journal:  Nephrol Dial Transplant       Date:  2011-03-17       Impact factor: 5.992

Review 4.  Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy.

Authors:  Waka Ohishi; Kazuaki Chayama
Journal:  Clin Exp Nephrol       Date:  2011-06-01       Impact factor: 2.801

Review 5.  Current trends in management of hepatitis B virus reactivation in the biologic therapy era.

Authors:  Claudio M Mastroianni; Miriam Lichtner; Rita Citton; Cosmo Del Borgo; Angela Rago; Helene Martini; Giuseppe Cimino; Vincenzo Vullo
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

6.  ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes.

Authors:  Kunihiro Yamagata; Joichi Usui; Chie Saito; Naoto Yamaguchi; Kouichi Hirayama; Kaori Mase; Masaki Kobayashi; Akio Koyama; Hitoshi Sugiyama; Kosaku Nitta; Takashi Wada; Eri Muso; Yoshihiro Arimura; Hirofumi Makino; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2012-02-18       Impact factor: 2.801

Review 7.  Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.

Authors:  J S Lubel; A G Testro; P W Angus
Journal:  Intern Med J       Date:  2007-10       Impact factor: 2.048

8.  Rituximab treatment of idiopathic membranous nephropathy.

Authors:  F C Fervenza; F G Cosio; S B Erickson; U Specks; A M Herzenberg; J J Dillon; N Leung; I M Cohen; D N Wochos; E Bergstralh; M Hladunewich; D C Cattran
Journal:  Kidney Int       Date:  2007-10-17       Impact factor: 10.612

9.  Management of hepatitis B reactivation in patients with lupus nephritis.

Authors:  Kai-Chung Tse; Susan Yung; Colin Tang; Terence Pok-Siu Yip; Tak Mao Chan
Journal:  Rheumatol Int       Date:  2009-01-22       Impact factor: 2.631

Review 10.  Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Masashi Mizokami; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2009-06-23       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.